Quick Answer
Alzamend Neuro, Inc. reported Operating Income Loss of -$4.50 million for the year ending 2025.
- Alzamend Neuro, Inc. showed an increase of +54.7% in Operating Income Loss from 2024 to 2025.
- This data is from Alzamend Neuro, Inc.'s annual report (Form 10-K), filed with the SEC on July 22, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$1.32 million | Q4 2020: -$1.30 million | Q1 2021: -$1.12 million | Q3 2021: -$2.31 million | Q4 2021: -$3.58 million | Q1 2022: -$2.56 million | Q3 2022: -$3.04 million | Q4 2022: -$3.11 million | Q1 2023: -$5.42 million | Q3 2023: -$3.53 million | Q4 2023: -$2.90 million | Q1 2024: -$2.66 million | Q3 2024: -$962.4 thousand | Q4 2024: -$1.36 million | Q1 2025: -$1.04 million | Q3 2025: -$2.70 million | Q4 2025: -$998.1 thousand.
- Over the full 6 years of available data (2020 to 2025), Alzamend Neuro, Inc.'s Operating Income Loss has declined by 1.6%.
- Historical annual values: Fiscal year 2025: -$4.50 million | Fiscal year 2024: -$9.94 million | Fiscal year 2023: -$14.87 million | Fiscal year 2022: -$12.32 million | Fiscal year 2021: -$4.95 million | Fiscal year 2020: -$4.42 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: